May 2026 Research Update

This month added an early human signal that CDD may leave a measurable fingerprint in the blood, especially in tiny particle packages called extracellular vesicles. In a small comparison, many proteins differed between people with CDD and neurotypical controls, and a smaller set of proteins rose or fell alongside higher clinical severity scores. In plain language, the study suggests researchers might be able to follow parts of CDD biology using a blood sample, but it is not yet a validated test. [1]

The protein changes clustered in areas that fit with how CDD affects the body, including how cells move cargo around (vesicle trafficking), cell structure (cytoskeleton), energy-making systems (mitochondria), and immune signaling. The researchers also reported 18 proteins that closely correlated with a CDD clinical severity scale, meaning people with higher severity tended to have higher or lower levels of these proteins in this dataset. A key uncertainty is what tissues these vesicle proteins came from, because blood vesicles can come from the brain and from the rest of the body. [1]

For families, this is mainly research that may matter later rather than something that changes care now. It helps clarify that scientists are getting closer to measurable signals in blood that could someday support tracking disease severity or treatment effects, if other studies confirm the same proteins in larger and more diverse groups. What remains uncertain is whether these signals are specific to CDD, how stable they are over time, and whether they reflect brain changes or changes elsewhere in the body. [1]

Two preclinical studies focused on building a clearer picture of what CDKL5 changes inside cells and brain circuits, and on identifying measurable signals that could be followed in experiments. One laboratory study reported that ganaxolone can inhibit a protein called PTP1B in cells and increased TRKB/BDNF signaling, which is part of how nerve cells respond to growth and support signals. A separate mouse study reported that brain wiring changes were not uniform across the whole brain, but instead showed specific regional network disruptions. [2] [3]

In neuronal cell models, ganaxolone inhibited PTP1B and boosted TRKB/BDNF signaling, with particularly notable effects in CDKL5 knockout cells where it also restored aspects of cell shape. The authors framed this as support for PTP1B as a possible target connected to CDKL5-related biology, but these results come from enzyme tests and cell experiments rather than people. In plain language, it suggests a potential way ganaxolone could influence cell signaling beyond seizure control, but it does not show what happens in patients. [2]

In Cdkl5 knockout mice, diffusion MRI-based mapping found that whole-brain network measures looked similar to controls, while certain regions and connections differed, including areas tied to movement/sensory processing and circuits involving the hippocampus, thalamus, amygdala, and hypothalamus. The study positioned these regional connectivity measures as possible biomarkers that could be tracked in research, including when testing therapies in animals. In plain language, it supports the idea that CDD-related changes may be circuit-specific rather than a single global "wiring" change, at least in this mouse model. [3]

For patients and caregivers, these findings are early-stage and mainly help explain where research is heading. The cell study may matter in the future if it leads to clearer biological readouts of how medicines affect nerve-cell signaling, but it does not establish a new use or expected effect of ganaxolone in daily life. The mouse imaging work may matter later if similar brain-network measures can be translated into human-friendly scans, but this study did not test that step. [2] [3]